Illinois is currently home to 2642 active clinical trials, seeking participants for engagement in research studies. These trials take place at a variety of cities in the state, including Chicago, Peoria, Springfield and Urbana. Whether you're a healthy volunteer interested in paid medical research or someone seeking trials related to a specific condition, the state offers a diverse array of opportunities in your vicinity.
A Clinical Trial of Tolcapone in Obsessive Compulsive Disorder
NCT05624528
Recruiting
The primary aim of the present study is to examine the efficacy and safety of tolcapone in adults with moderate to severe OCD.
Gender:
ALL
Ages:
Between 18 years and 65 years
Trial Updated:
06/02/2025
Locations: University of Chicago Medical Center, Chicago, Illinois
Conditions: Obsessive-Compulsive Disorder, OCD
Register for Updates
Study of Vorasidenib and Pembrolizumab Combination in Recurrent or Progressive IDH-1 Mutant Glioma
NCT05484622
Recruiting
Vorasidenib in combination with pembrolizumab in participants with recurrent or progressive isocitrate dehydrogenase-1 (IDH-1) mutant Glioma.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Northwestern University (Site: 840123), Chicago, Illinois
Conditions: Astrocytoma, Oligodendroglioma
Register for Updates
A Study to Determine the Efficacy and Safety of Tividenofusp Alfa (DNL310) vs Idursulfase in Pediatric and Young Adult Participants With Neuronopathic (nMPS II) or Non-Neuronopathic Mucopolysaccharidosis Type II (nnMPS II)
NCT05371613
Recruiting
This is a Phase 2/3, multiregional, two-arm, double-blind, randomized, active (standard-of-care)-controlled study of the efficacy and safety of tividenofusp alfa (DNL310), an investigational central nervous system (CNS)-penetrant enzyme-replacement therapy (ERT) for mucopolysaccharidosis type II (MPS II). Participants may also qualify to enter an open-label treatment phase with DNL310 or idursulfase based on pre-specified criteria.
Gender:
ALL
Ages:
Between 2 years and 26 years
Trial Updated:
06/02/2025
Locations: Ann and Robert H Lurie Children's Hospital of Chicago, Chicago, Illinois
Conditions: Mucopolysaccharidosis II
Register for Updates
Emicizumab in Patients With Acquired Hemophilia A
NCT05345197
Recruiting
This is a phase II multicenter open-label, single-arm prospective study to evaluate the efficacy of prophylactic emicizumab administered on a scheduled basis to prevent bleeds in patients with acquired hemophilia A (AHA).
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Bleeding and Clotting Disorders Institute, Peoria, Illinois
Conditions: Acquired Hemophilia A
Register for Updates
SELUTION4BTK Trial
NCT05055297
Recruiting
This study aims to demonstrate superior efficacy and equivalent safety of the SELUTION SLR™ DEB 014 compared to plain (uncoated) balloon angioplasty in the treatment of peripheral arterial disease (PAD) in the BTK arteries in CLTI patients.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Rush University Medical Center, Chicago, Illinois
Conditions: Peripheral Arterial Disease, Chronic Limb-Threatening Ischemia Nos of Native Arteries of Extremities
Register for Updates
CA-4948-101: Open-Label, Dose Escalation and Expansion Trial of Emavusertib (CA-4948) in Relapsed or Refractory Primary Central Nervous System Lymphoma (R/R PCNSL)
NCT03328078
Recruiting
This is a multi-center, open-label study to evaluate the safety, pharmacokinetics (PK), and anti-cancer activity of oral administration of emavusertib alone or in combination with ibrutinib in adult participants with relapsed or refractory (R/R) hematologic malignancies. This trial will be completed in four parts. In Part A1, emavusertib will be evaluated first in a dose escalating monotherapy setting to establish the safety and tolerability (complete). In Part A2, emavusertib will be evaluated... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: Northwestern Memorial Hospital, Chicago, Illinois
Conditions: Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma
Register for Updates
Venetoclax and Chemotherapy as Frontline Therapy in Older Patients and Patients With Relapsed/Refractory ALL
NCT03319901
Recruiting
This research study is studying a medication called Venetoclax and a chemotherapy regimen as a possible treatment for Acute Lymphoblastic Leukemia. The drugs involved in this study are: * Venetoclax * Standard Chemotherapy (which includes cyclophosphamide, vincristine, doxorubicin, dexamethasone, methotrexate, 6-mercaptopurine, etoposide, and cytarabine
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/02/2025
Locations: University of Chicago, Chicago, Illinois
Conditions: Leukemia
Register for Updates
Prevalence of Antibodies and Cytokines in Participants With Chronic Granulomatous Disease
NCT06605378
Recruiting
This research study is designed to assess the prevalence of specific antibodies and inflammatory cytokines in adult and pediatric participants with CGD.
Gender:
ALL
Ages:
All
Trial Updated:
05/30/2025
Locations: Home-based telemedicine, Springfield, Illinois
Conditions: Chronic Granulomatous Disease (CGD)
Register for Updates
Falcon Real World Evidence Registry
NCT06589310
Recruiting
This is a multi-site registry of patients receiving the Exact Sciences Multicancer Early Detection (MCED) test.
Gender:
ALL
Ages:
Between 50 years and 80 years
Trial Updated:
05/30/2025
Locations: Endeavor Health, Evanston, Illinois
Conditions: Cancer
Register for Updates
Evaluation of the Safety and Effectiveness of ARTIA Reconstructive Tissue Matrix Breast Reconstruction (ADORA) in Adult Participants
NCT06575192
Recruiting
The purpose of this study is to evaluate the safety and effectiveness of ARTIA in adult participants undergoing immediate, two-stage, implant-based breast reconstruction post-mastectomy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: Endeavor Health /ID# 266302, Northbrook, Illinois
Conditions: Breast Reconstruction
Register for Updates
Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
NCT06293898
Recruiting
The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-M07D1 in patients with HER2 expressing advanced tumors.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
05/30/2025
Locations: University of Illinois Cancer Center, Chicago, Illinois
Conditions: Endometrial Cancer, Cervical Cancer, Ovarian Cancer, Urothelial Carcinoma, Biliary Tract Cancer, Breast Cancer, Lung Cancer, Gastric Cancer, Gastroesophageal-junction Cancer, Esophageal Cancer
Register for Updates
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
NCT05172726
Recruiting
This is an open-label, multi-center, Phase 3 study to evaluate tapinarof cream, 1% in pediatric subjects with plaque psoriasis.
Gender:
ALL
Ages:
Between 2 years and 17 years
Trial Updated:
05/30/2025
Locations: Clinical Site, Chicago, Illinois
Conditions: Plaque Psoriasis
Register for Updates